en · de · es
bpc-157-notes.peptides5388.com › Info › Origin And Peptide Identity — Reference Sheet

Origin And Peptide Identity — Reference Sheet

By Editorial Desk · published 2025-12-21 · last reviewed 2026-01-25 · Info

A practical reference on peptide purity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.

Origin and Peptide Identity

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Stability, Storage, and Analytical Testing

A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.

Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.

Bpc-157 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderAssessed by visual inspection under ordinary laboratory lighting
Molecular massApproximately 1419 DaMonoisotopic mass for the fifteen-residue sequence
Solubility classFreely soluble in waterStock solutions commonly prepared in water or aqueous buffer
Typical storage temperature-20 °C or below, desiccatedLyophilized powder; repeated freeze-thaw cycles are usually avoided
Common analytical methodReversed-phase HPLC with UV detectionFrequently paired with mass spectrometry to confirm identity

Handling, Stability, and Quality Checks

The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.

BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.

Related pages on this site

Research Literature and Evidence Gaps

Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.

Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.

Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.

Identity And Research Background

The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.

Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.

Background and Research Status

Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.

BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.

Further detail

== Metabolism == The half-life of pyridoxine varies according to different sources: one source suggests that the half-life of pyridoxine is up to 20 days, while another source indicates half-life of vitamin B6 is in range of 25 to 33 days. After considering the different sources, it can be concluded that the half-life of pyridoxine is typically measured in several weeks.

== History == Zopiclone was developed and first introduced in 1986 by Rhône-Poulenc S.A., now part of Sanofi, the main worldwide manufacturer. Initially, it was promoted as an improvement on benzodiazepines, which has since been disproven. On April 4, 2005, the U.S. Drug Enforcement Administration listed zopiclone under schedule IV, due to evidence that the drug has addictive properties similar to benzodiazepines. Zopiclone, as traditionally sold worldwide, is a racemic mixture of two stereoisomers, only one of which is active. In 2005, the pharmaceutical company Sepracor of Marlborough, Massachusetts, began marketing the active stereoisomer eszopiclone under the name Lunesta in the United States. This had the consequence of placing what is a generic drug in most of the world under patent control in the United States. Generic forms of Lunesta have since become available in the United States. Zopiclone is currently available off-patent in a number of European countries, Brazil, Canada, Hong Kong, and New Zealand. The eszopiclone/zopiclone difference is in the dosage—the strongest eszopiclone dosage contains 3 mg of the therapeutic stereoisomer, whereas the highest zopiclone dosage (10 mg) contains 5 mg of the active stereoisomer.

There is evidence to suggest that excitatory amino acids like quisqualic acid play a significant role in the induction of cell death following stroke, hypoxia-ischemia, and traumatic brain injury . Studies involving the binding of quisqualic acid have indicated that the amino acid does not show selectivity for a singular specific receptor subtype, which was initially identified as the quisqualate receptor. Instead, it demonstrates high affinity for other types of excitatory amino acid receptors, including kainate, AMPA, and metabotropic receptors, as well as some transport sites, such as the chloride-dependent L-AP4-sensitive sites. In addition, it also exhibits affinity for certain enzymes responsible for cleaving dipeptides, including the enzyme responsible for cleaving N-acetyl-aspartylglutamate (NAALADase) . Regarding bioavailability, no database information is present, as there is limited research on its pharmacokinetics. However, even though the bioavailability is not well established, studies in rats suggest that age may play a role in the presence of administered quisqualic acid effects. An experiment which was done on rats within two age groups (20-days-old and 60-days-old) showed that, when given quisqualic acid microinjections, 60-day-old rats had more seizures compared to the younger rats. Additionally, the rats were given the same amount of quisqualic acid, however the immature animals received a higher dosage per body weight, implying that the harm inflicted by the excitatory amino acid may have been comparatively lower in the younger animals.

Sources: en.wikipedia.org

Supporting material

== Occupational exposure == Occupational exposure to PFAS occurs in numerous industries due to the widespread use of the chemicals in products and as an element of industrial process streams. People who are exposed to PFAS through their jobs typically have higher blood concentrations of PFAS than the general population due to their elevated risk for accidental ingestion, inhalation exposure, and skin contact of PFAS. Occupational exposure can occur both during production of PFAS at fluorochemical facilities and in other industries that utilize these chemicals in their processes and products.

=== Recent Interests on PIDD1 === Over the past few years, biallelic pathogenic variants in the CRADD gene have been strongly associated with a rare neurodevelopmental disorder (MRT34; MIM 614499), known as the "thin" lissencephaly (TLIS) variant. This disorder is characterized by pachygyria, primarily affecting the anterior regions of the brain, and is accompanied by megalencephaly, epilepsy, and intellectual disability (ID). This discovery has drawn increased attention to the PIDDosome complex, revealing a wider array of biological functions beyond its conventional role in apoptosis triggered by DNA damage. In this regard, PIDD1, a CRADD-interacting protein, functions as a sensor that monitors centrosome numbers and plays a vital role in controlling cellular differentiation during key processes such as organogenesis and tissue regeneration. Recently, four homozygous variants in the PIDD1 gene have been identified among 11 individuals from five separate families, all of whom present with nonsyndromic intellectual disability. Nevertheless, comprehensive clinical and neuroimaging data for these cases are limited.

The Scud missiles targeting Israel were relatively ineffective, as firing at extreme range resulted in a dramatic reduction in accuracy and payload. Two Israeli civilians died as a direct result of the missile attacks. Between 11 and 74 died from incorrect use of gas masks, heart attacks, and incorrect use of the anti-chemical weapons drug atropine. Approximately 230 Israelis were injured. Extensive property damage was also caused, and, according to the Israel Ministry of Foreign Affairs, "Damage to general property consisted of 1,302 houses, 6,142 apartments, 23 public buildings, 200 shops and 50 cars." It was feared that Iraq would fire missiles filled with nerve agents such as sarin. As a result, Israel's government issued gas masks to its citizens. When the first Iraqi missiles hit Israel, some people injected themselves with an antidote for nerve gas. It has been suggested that the sturdy construction techniques used in Israeli cities, coupled with the fact that Scuds were only launched at night, played an important role in limiting the number of casualties from Scud attacks.

== Temperature == The cabbage looper migration patterns are highly temperature dependent, as temperature can impact development. It has the greatest impact on pupation, where pupae often cease to finish metamorphosis if grown at 10 °C (50 °F). Even if pupae are transferred from 10 °C to 12.7 °C (54.86 °F), they often emerge deformed, sometimes developing an extra instar. Temperatures above 35 °C (95 °F) also result in physical deformations in adults, such as poor wing development. Mating and flight are negatively impacted by temperatures above 32 °C (89.6 °F) and below 16 °C, which may explain why cabbage loopers migrate to northern regions once temperatures reach 16 °C. The time between female calling and male response increases as temperature increases, but when the temperature reaches 27 °C (80.6 °F), mating increases. At the same time, oviposition and longevity decrease, with hatching almost ceasing at 32 °C. The embryo itself is actually quite resilient, as it is able to develop at 10 °C and at 40 °C (104 °F). However, although it is developed, it is unable to hatch. Temperature does not affect the pheromone-sensitive receptor neurons.

Sources: en.wikipedia.org

Notes from published material

== Biological function and disease relevance == In E. coli, OmpT is a housekeeping protease that degrades foreign peptide material that the bacteria encounters. Because of its ability to cleave peptides present in its surrounding environment, OmpT is associated with several pathologies.

Specific plan elements included defense and non-defense spending freezes for 4–5 years, income tax reform, elimination of tax expenditures, and a national sales tax or value-added tax (VAT). The Hamilton Project published a guidebook with 15 different proposals from various policy and budget experts in February, 2013. The authors were asked to provide pragmatic, evidenced-based proposals that would both reduce the deficit and bring broader economic benefits. Proposals included a value added tax and reductions to tax expenditures, among others.

== Genetics and disease relevance == In humans, enteropeptidase is encoded by the TMPRSS15 gene (also known as ENTK, and previously as PRSS7) on chromosome 21q21. Some nonsense and frameshift mutations in this gene lead to a rare recessive disorder characterised by severe failure to thrive in affected infants, due to enteropeptidase deficiency. Enteropeptidase mRNA expression is limited to the proximal small intestine, and the protein is found in enterocytes of duodenum and proximal jejunum. Upon secretion from the pancreas into the duodenum, trypsinogen encounters enteropeptidase and is activated. Trypsin then cleaves and activates other pancreatic serine protease zymogens (chymotrypsinogen and proelastases), metalloprotease zymogens (procarboxypeptidases) and prolipases. By means of this simple two-step cascade, the destructive activity of these digestive hydrolases is confined to the lumen of the intestine. The physiological importance of this pathway is demonstrated by the severe intestinal malabsorption caused by congenital deficiency of enteropeptidase. This condition can be life-threatening, but responds to oral supplementation with pancreatic extract.

== Applications == Orbitrap-based mass spectrometers are used in proteomics and are also used in life science mass spectrometry such as metabolism, metabolomics, environmental, food and safety analysis. Most of them are interfaced to liquid chromatography separations, though they are also used with gas chromatography, secondary ion and ambient ionization methods. Orbitrap mass spectrometers have also been used to determine bulk and position-specific isotope ratios at natural abundance.

Narrated by Stephen Rashbrook, produced by Nick Catliff, directed by Henry Singer, made by Lion Television and Sandpaper Films. Shown on Monday 7 February 2000 on The Nature of Things in Canada 27 September Near Miss, about ATC, the 1960 New York mid-air collision in December 1960; around 7,500 aircraft visit the three airports each day; LaGuardia Airport has two conjoined runways that operate in a strange mixed way; on 3 April 1998 there was a near miss; USAir Flight 5050 in September 1989; Colombian Avianca Flight 52 in January 1990 approached John F. Kennedy International Airport when running out of fuel, when a 4-hour flight turned into 6 hours due to weather. Narrated by Jack Davenport, directed by Jeremy Llewellyn-Jones, produced by Emma Bowman, made by Windfall Films and The Learning Channel (TLC). On All 4 4 October Curing the Incurable, the strange teratoma cells; Paul R. Sanberg of the University of South Florida; Irving Weissman of Stanford University; pathologist John Goepel; Peter Andrews (biologist); neurosurgeon Douglas Kondziolka of the University of Pittsburgh Medical Center, and stereotactic surgery; John Sinden of ReNeuron; Ann Tsukamoto of CytoTherapeutics. Narrated by David Malone, made by Boa Picture Company 20 December Talking with Aliens, an Equinox Special, with zoologist Denise L. Herzing, made by Pioneer Films

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 chemically?

It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.

How is the material usually supplied?

It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.

Does the abbreviation stand for a chemical name?

The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.

Why is the powder kept frozen?

Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.

Network